Following the results of several studies, rheumatologist Jonathan Graf has cautioned patients with diabetes to avoid using thiazolidinediones as they appear to reduce bone density and elevate fracture risk. However, taking lower doses of thiazolidinediones in combination with either metformin or incretin drugs may still help patients achieve efficient diabetes control without risking bone health, Graf said.

Related Summaries